GP Mast 200

GP Mast 200 – Drostanolone Enanthate Overview

GP Mast 200 is an injectable anabolic steroid from Geneza Pharmaceuticals containing Drostanolone Enanthate at 200 mg/ml in a 10 ml vial. Drostanolone Enanthate is the long-ester formulation of Masteron – the same DHT-derived, non-aromatizing compound as Drostanolone Propionate (GP Mast 100), but with an Enanthate ester that extends the half-life to approximately 7-10 days and reduces injection frequency to twice-weekly. Commonly searched as Masteron E, Mast E, Mast 200, Masteron Enanthate, Drostanolone Enanthate, and Geneza Mast E.

What Is Drostanolone Enanthate?

Drostanolone Enanthate is a DHT (dihydrotestosterone) derivative – the long-ester version of Drostanolone Propionate. Like Drostanolone Propionate, it does not aromatize to estrogen. The pharmacological profile is identical: DHT-derived, non-aromatizing, androgenic, with mild anti-estrogenic properties cited in community references when used alongside aromatizing testosterone compounds. The key practical difference from Mast 100 (Propionate ester) is the longer Enanthate ester – half-life approximately 7-10 days versus 2-3 days – which allows a twice-weekly injection schedule instead of EOD, at the cost of slower blood level stabilization and an extended clearance window before PCT. 200 mg/ml is the standard concentration for injectable Drostanolone Enanthate, compared to 100 mg/ml for the Propionate ester.

Why Users Search for GP Mast 200

Masteron Enanthate is primarily searched by users building long-ester cutting stacks where ester-matching with Testosterone Enanthate and Trenbolone Enanthate is practical. The long-ester cutting combination – Testosterone Enanthate + Trenbolone Enanthate + Drostanolone Enanthate – is the most consistently referenced Mast 200 stack framework, providing twice-weekly injection compatibility across all three compounds. Mast E vs Mast Prop ester comparison is the most searched Masteron differentiation topic. The longer ester makes Mast 200 a referenced choice for users who prioritize injection frequency reduction over the faster clearance and earlier PCT timing offered by Mast 100.

• Active substance: Drostanolone Enanthate – DHT-derived, non-aromatizing, long-ester Masteron injectable.
• Concentration: 200 mg/ml in a 10 ml vial – 2000 mg Drostanolone Enanthate total content.
• Injection schedule: Twice-weekly injections referenced for blood level stability with the Enanthate ester.
• Common names: Masteron E, Mast E, Mast 200, Masteron Enanthate, Drostanolone Enanthate, Drost E, Geneza Mast E.
• Cycle context: Long-ester cutting stack (Test Enanth + Tren Enanth + Mast 200), ester-matched twice-weekly cutting framework.

GP Mast 200 Dose and Concentration Information

GP Mast 200 is listed at 200 mg/ml. A 10 ml vial contains 2000 mg Drostanolone Enanthate in total. The Enanthate ester produces a half-life of approximately 7-10 days, making twice-weekly injections the most consistently referenced schedule for blood level stability. This contrasts with Drostanolone Propionate (GP Mast 100, 100 mg/ml), which requires EOD injections due to its 2-3 day half-life.

Concentration and Ester Context

200 mg/ml is the standard concentration for injectable Drostanolone Enanthate. The higher concentration relative to Mast 100 (100 mg/ml) reflects both the Enanthate ester’s molecular weight contribution and the standard industry convention for long-ester Drostanolone. Blood levels stabilize more slowly with the Enanthate ester than with the Propionate – a 1-2 week ramp-up period before peak steady state is cited in references comparing ester formats. PCT timing after GP Mast 200 is approximately 14 days post-last-injection, compared to 3-5 days for Mast 100 – the primary practical trade-off between the two ester formats for cycle planning.

Bloodwork and Monitoring Context

Drostanolone Enanthate does not aromatize, so estrogen-specific monitoring is not attributed to Mast 200 itself – however, estrogen monitoring from any aromatizing testosterone compounds used alongside remains standard. Lipid panel (HDL suppression), androgenic markers (hair loss assessment in predisposed individuals, acne), hematocrit, and blood pressure are the cited monitoring references for Masteron Enanthate cycles. Drostanolone does not produce significant liver stress. HPTA suppression occurs and post-cycle therapy is required.

• Concentration: 200 mg/ml – standard Drostanolone Enanthate injectable concentration.
• Total content: 2000 mg Drostanolone Enanthate per 10 ml vial.
• Injection schedule: Twice-weekly most consistently cited for blood level stability with the Enanthate ester.
• PCT timing: Approximately 14 days post-last-injection – Enanthate ester clearance governs timing.
• Bloodwork context: Lipid panel (HDL), androgenic markers, hematocrit, blood pressure – no significant liver or direct estrogen-specific concerns from Masteron itself.
• Ester comparison: GP Mast 100 (Drostanolone Propionate, 100 mg/ml) allows EOD injections and PCT 3-5 days post-last-injection – the primary timing trade-off versus Mast 200.